Mucoadhesive TannicAcid-Cross-Linked Nanogels forReactive Oxygen Species Scavenging and Enhanced Ocular TherapeuticDelivery

Mucoadhesive nanoparticles show promise for mucosal drug delivery, but ocular applications remain limited by rapid clearance, poor retention, and insufficient drug encapsulation. Existing systems struggle to deliver a full spectrum of therapeutics, hydrophobic drugs, hydrophilic drugs, and proteins, despite the critical need for such versatility in treating complex ocular diseases. Many eye conditions, including infection, inflammation, and degenerative disorder, require combination therapies or multidrug regimens for optimal therapeutic outcomes. To address these limitations, we developed a biocompatible tannic acid (TA)-cross-linked nanogel (NG) platform with robust mucoadhesion, anti-inflammatory, reactive oxygen species (ROS) scavenging properties, and sustained drug-release capabilities. The NGs were synthesized from a temperature-responsive poly(ethylene glycol)-based copolymer that self-aggregates above its lower critical solution temperature and is cross-linked with TA. TA’s polyphenolic structure enables multimodal mucoadhesion and antioxidant activity, enhancing ocular retention and protecting against ROS-induced damage. The NGs achieved high loading efficiency (>80%) for diverse therapeutics, including moxifloxacin, a hydrophilic antibiotic; dexamethasone (Dex), a hydrophobic anti-inflammatory drug; as well as bovine serum albumin, used as a model protein to explore potential for protein encapsulation. In proof-of-concept studies, Dex-loaded NGs demonstrated sustained release (>24 days) and therapeutic efficacy <i>in vitro</i> and <i>in vivo</i>. Blank NGs also exhibited anti-inflammatory activity <i>in vivo</i>, comparable to Dex-loaded NGs in an acute model of ocular inflammation, demonstrating their intrinsic therapeutic potential. By enabling delivery of multiple therapeutic classes while providing inherent anti-inflammatory function, this TA-cross-linked NG platform offers a versatile and effective strategy for managing complex ocular diseases.

Publication Details

Journal
Figshare
Published
2025-07-23
DOI
https://doi.org/10.1021/acsnano.5c02002.s001
Primary Topic
Libraries and Information Services
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mucoadhesive TannicAcid-Cross-Linked Nanogels forReactive Oxygen Species Scavenging and Enhanced Ocular TherapeuticDelivery

Figshare
Libraries and Information Services
article

Mucoadhesive TannicAcid-Cross-Linked Nanogels forReactive Oxygen Species Scavenging and Enhanced Ocular TherapeuticDelivery

article en

Abstract

Mucoadhesive nanoparticles show promise for mucosal drug delivery, but ocular applications remain limited by rapid clearance, poor retention, and insufficient drug encapsulation. Existing systems struggle to deliver a full spectrum of therapeutics, hydrophobic drugs, hydrophilic drugs, and proteins, despite the critical need for such versatility in treating complex ocular diseases. Many eye conditions, including infection, inflammation, and degenerative disorder, require combination therapies or multidrug regimens for optimal therapeutic outcomes. To address these limitations, we developed a biocompatible tannic acid (TA)-cross-linked nanogel (NG) platform with robust mucoadhesion, anti-inflammatory, reactive oxygen species (ROS) scavenging properties, and sustained drug-release capabilities. The NGs were synthesized from a temperature-responsive poly(ethylene glycol)-based copolymer that self-aggregates above its lower critical solution temperature and is cross-linked with TA. TA’s polyphenolic structure enables multimodal mucoadhesion and antioxidant activity, enhancing ocular retention and protecting against ROS-induced damage. The NGs achieved high loading efficiency (>80%) for diverse therapeutics, including moxifloxacin, a hydrophilic antibiotic; dexamethasone (Dex), a hydrophobic anti-inflammatory drug; as well as bovine serum albumin, used as a model protein to explore potential for protein encapsulation. In proof-of-concept studies, Dex-loaded NGs demonstrated sustained release (>24 days) and therapeutic efficacy <i>in vitro</i> and <i>in vivo</i>. Blank NGs also exhibited anti-inflammatory activity <i>in vivo</i>, comparable to Dex-loaded NGs in an acute model of ocular inflammation, demonstrating their intrinsic therapeutic potential. By enabling delivery of multiple therapeutic classes while providing inherent anti-inflammatory function, this TA-cross-linked NG platform offers a versatile and effective strategy for managing complex ocular diseases.

Figshare
No poverty
Openalex Percentile: Top 52%
Libraries and Information Services
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Mucoadhesive TannicAcid-Cross-Linked Nanogels forReactive Oxygen Species Scavenging and Enhanced Ocular TherapeuticDelivery · Figshare (2025) | TGRS Research Map | TGRS